FDA should consider allowing sponsors of treatments targeting a single species of bacteria to select from, and possibly combine, studies from a menu of options to evaluate safety and effectiveness, FDA's Antimicrobial Drugs Advisory Committee suggested in a recent discussion.
The agency did not pose voting questions to the panel at its April 13 meeting. But the discussion indicated general agreement on the public health need to develop these kinds...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?